Corcept Therapeutics Incorporated, a company focused on developing medications for severe endocrine, oncological, metabolic, and neurological disorders, has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). This application is for their selective cortisol modulator, relacorilant, as a treatment for patients with platinum-resistant ovarian cancer. This marks a significant milestone for Corcept, as it now has two NDAs under FDA review. The submission is backed by positive results from Phase 3 ROSELLA and Phase 2 trials, showing improved patient outcomes without increasing the safety burden. The company is preparing for potential regulatory approval to offer better treatment options for patients.